Evidence map›Paper›PMID 42410279›Full record

ArticleCardiovascular intervention and therapeutics2026

Ischemic time is associated with procedure-related no-reflow/slow-flow during perfusion balloon-assisted percutaneous coronary intervention in acute coronary syndrome.

Hiroshi Abe, Dai Ozaki, Masato Tomaru, Takamasa Suzuki, Mari Sumiyoshi, Midori Kakihara, Masaaki Maki, Ryousuke Shimai, Hiroyuki Isogai, Yuki Yasuda and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Cardiovascular intervention and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Hiroshi AbeDepartment of Cardiology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu, 279-0021, Japan.
Dai OzakiDepartment of Cardiology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu, 279-0021, Japan. dozaki@juntendo.ac.jp.ORCID http://orcid.org/0000-0003-3012-6248
Masato TomaruDepartment of Cardiology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu, 279-0021, Japan.
Takamasa SuzukiDepartment of Cardiology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu, 279-0021, Japan.
Mari SumiyoshiDepartment of Cardiology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu, 279-0021, Japan.
Midori KakiharaDepartment of Cardiology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu, 279-0021, Japan.
Masaaki MakiDepartment of Cardiology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu, 279-0021, Japan.
Ryousuke ShimaiDepartment of Cardiology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu, 279-0021, Japan.
Hiroyuki IsogaiDepartment of Cardiology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu, 279-0021, Japan.
Yuki YasudaDepartment of Cardiology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu, 279-0021, Japan.
Kiyoshi TakasuDepartment of Cardiology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu, 279-0021, Japan.
Fuminori OdagiriDepartment of Cardiology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu, 279-0021, Japan.
Kazuhisa TakamuraDepartment of Cardiology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu, 279-0021, Japan.
Tetsuro MiyazakiLaboratory of Bioregulatory Clinical Pharmacology, Faculty of Pharmacy, Juntendo University, 6-8-1 Hinode, Urayasu, 279-0013, Japan.
Takashi TokanoDepartment of Cardiology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu, 279-0021, Japan.
Tohru MinaminoDepartment of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Perfusion balloons have been shown to reduce the incidence of no-reflow/slow-flow in thrombotic lesions among patients with acute coronary syndrome (ACS). However, predictors of procedure-related no-reflow/slow-flow during perfusion balloon-assisted percutaneous coronary intervention (PCI) remain poorly defined. We conducted a single-center, retrospective cohort study of patients with ACS who underwent perfusion balloon-assisted PCI following restoration of thrombolysis in myocardial infarction (TIMI) grade 3 flow. The primary outcome was procedure-related no-reflow/slow-flow occurring during any subsequent procedural step after initial flow restoration. A total of 54 patients with ACS were included in the analysis, of whom 9 (16.7%) developed procedure-related no-reflow/slow-flow. When stratified by ischemic time, no-reflow/slow-flow occurred more frequently in patients with an onset-to-PCI time greater than 6 h than in those treated within 6 h (p < 0.01). In multivariate analysis, ischemic time greater than 6 h was associated with procedure-related no-reflow/slow-flow (adjusted odds ratio, 9.79; 95% confidence interval [CI], 1.54-123.41; p = 0.015). The multivariable model demonstrated good discriminative performance, with an area under the receiver operating characteristic curve of 0.80 (95% CI, 0.60-0.99). Among patients with ACS undergoing perfusion balloon-assisted PCI, prolonged ischemic time was associated with procedure-related no-reflow/slow-flow.

Indexed as

Acute Coronary SyndromeAngioplasty, Balloon, CoronaryCoronary CirculationNo-Reflow PhenomenonPercutaneous Coronary InterventionAgedCoronary AngiographyFemaleHumansMaleMiddle AgedRetrospective StudiesTime FactorsAcute coronary syndromePercutaneous coronary interventionPerfusion balloonSlow-flow

Identifiers

PMID42410279

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.